ライフサイエンスコーパス: macular degeneration

1 pigment epithelium), and H35.50 (unspecified macular degeneration).

2 used on diabetic retinopathy and age-related macular degeneration.

3 etinitis pigmentosa, but also in age-related macular degeneration.

4 ise likely causal biomarkers for age-related macular degeneration.

5 of vision loss in patients with age-related macular degeneration.

6 get for diabetic retinopathy and age-related macular degeneration.

7 on for patients with neovascular age-related macular degeneration.

8 m many retinal diseases, such as age-related macular degeneration.

9 lions of patients suffering from age-related macular degeneration.

10 taract surgery, corneal transplantation, and macular degeneration.

11 ible blindness in the setting of age-related macular degeneration.

12 liferative vitreoretinopathy and age-related macular degeneration.

13 nd choroidal vascular disease in age-related macular degeneration.

14 isual outcomes for patients with age-related macular degeneration.

15 n eye diseases like glaucoma and age-related macular degeneration.

16 macular degeneration (AMD) and 2 with myopic macular degeneration.

17 al ocular diseases including keratoconus and macular degeneration.

18 ambiguity about cone survival in age-related macular degeneration.

19 her macular disease including AMD and myopic macular degeneration.

20 mes and drives the pathogenesis of Stargardt macular degeneration.

21 tients with advanced neovascular age-related macular degeneration.

22 recommended for patients who are at risk for macular degeneration.

23 te unexpected cell types in diseases such as macular degeneration.

24 tics and diagnostics directed at age-related macular degeneration.

25 s less than that for other diseases, such as macular degeneration.

26 atrophy, and 2 eyes (2.8%) developed cystoid macular degeneration.

27 atients affected by dry atrophic age-related macular degeneration.

28 nd monitoring human eye disorders, including macular degeneration.

29 membrane probably also has implications for macular degeneration.

30 get in patients with neovascular age-related macular degeneration.

31 y (GA) secondary to nonexudative age-related macular degeneration.

32 ells to treat conditions such as age-related macular degeneration.

33 lytic uremic syndrome (aHUS) and age-related macular degeneration.

34 treatment schemes in neovascular age-related macular degeneration.

35 es like retinitis pigmentosa and age-related macular degeneration.

36 r (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%).

37 r indirect costs associated with age-related macular degeneration ($17 379.41-$657 406.55).

38 commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retiniti

39 abnormalities (26.6% versus 7.3%), exudative macular degeneration (5.2% versus 0.1%), and geographic

40 bservational study and found that history of macular degeneration (a proxy for complement-activation

41 Macular degenerations affect vision the most and are cur

42 ing hypothesis of the Alabama Study on Early Macular Degeneration (ALSTAR2) is that early AMD is a di

43 bnormal deposits associated with age-related macular degeneration, Alzheimer's disease, and many othe

44 Age-related macular degeneration (AMD) - the leading cause of vision

45 Age-related macular degeneration (AMD) affects millions of people an

46 Age-related macular degeneration (AMD) affects the retinal pigment e

47 isposes individuals to acquiring age-related macular degeneration (AMD) after aging.

48 s were diagnosed with coincident age-related macular degeneration (AMD) and 2 with myopic macular deg

49 to 90 years with GA secondary to age-related macular degeneration (AMD) and best-corrected visual acu

50 ssociated with increased risk of age-related macular degeneration (AMD) and disease progression, but

51 many ocular diseases, including age-related macular degeneration (AMD) and glaucoma.

52 and anxiety among subjects with age-related macular degeneration (AMD) and its association with AMD

53 sociated with the development of age-related macular degeneration (AMD) and other complementopathies.

54 susceptible genetic variants to age-related macular degeneration (AMD) and response to as-needed int

55 ges of patients with neovascular age-related macular degeneration (AMD) and to demonstrate its use to

56 non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendation

57 icity on the association between age-related macular degeneration (AMD) and vision-specific functioni

58 t prediction models for advanced age-related macular degeneration (AMD) are based on a restrictive se

59 drusen and without nGA nor late age-related macular degeneration (AMD) at baseline were included.

60 he progression of nonneovascular age-related macular degeneration (AMD) attributed to anteriorly migr

61 d in eyes with large drusen from age-related macular degeneration (AMD) before and after the drusen s

62 tify metabolites associated with age-related macular degeneration (AMD) by performing the largest met

63 ecline in the risk of developing age-related macular degeneration (AMD) continued for people born dur

64 nning may be secondary to active age-related macular degeneration (AMD) disease progression in both e

65 SIs to assess visual function in age-related macular degeneration (AMD) found CSI guided analysis det

66 o slow or prevent progression of age-related macular degeneration (AMD) from its early stages to visi

67 Offspring of parent(s) with age-related macular degeneration (AMD) have a 45% lifetime risk of d

68 gene and their association with age-related macular degeneration (AMD) have been described.

69 iction models for progression of age-related macular degeneration (AMD) have been developed, but the

70 y population, worldwide cases of age-related macular degeneration (AMD) have seen a dramatic increase

71 ve eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison with eyes with

72 The status of age-related macular degeneration (AMD) in the fellow eye has been us

73 Age-related macular degeneration (AMD) is a chronic eye condition th

74 Age-related macular degeneration (AMD) is a chronic, multifactorial

75 Age-related macular degeneration (AMD) is a common multifactorial di

76 Age-related Macular Degeneration (AMD) is a complex eye disease, whi

77 (VEGF) treatment of neovascular age-related macular degeneration (AMD) is a highly effective advance

78 Age-related macular degeneration (AMD) is a leading cause of blindne

79 Age-related macular degeneration (AMD) is a leading cause of irrever

80 Age-related macular degeneration (AMD) is a major cause of visual im

81 Age-related macular degeneration (AMD) is a multifactorial chronic d

82 Age-related macular degeneration (AMD) is a progressive disease of t

83 Early age-related macular degeneration (AMD) is characterized by degenerat

84 rongest susceptibility genes for age-related macular degeneration (AMD) is complement factor H (CFH);

85 Age-related macular degeneration (AMD) is highly prevalent among the

86 ould eat to reduce their risk of age-related macular degeneration (AMD) is still unclear.

87 Age-related macular degeneration (AMD) is the leading cause of blind

88 Age-related macular degeneration (AMD) is the leading cause of irrev

89 Age-related macular degeneration (AMD) is the leading cause of legal

90 Age related macular degeneration (AMD) is the most common blinding d

91 Age-related macular degeneration (AMD) is the most common cause of b

92 Age-related macular degeneration (AMD) is the most common cause of b

93 Age-related macular degeneration (AMD) is the primary cause of blind

94 To evaluate the impact of age-related macular degeneration (AMD) on short out-loud and sustain

95 thological neovascularization in age-related macular degeneration (AMD) or diabetic macular edema (DM

96 assess whether older adults with age-related macular degeneration (AMD) or glaucoma performed worse o

97 n but are strongly implicated in age-related macular degeneration (AMD) pathogenesis, a second single

98 noids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis.

99 LLQ) in patients with a range of age-related macular degeneration (AMD) severity are associated with

100 Age-related macular degeneration (AMD) showed moderate agreement (ka

101 t often in eyes with neovascular age-related macular degeneration (AMD) that had type 1 macular neova

102 ophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and

103 bolomic profile of patients with age-related macular degeneration (AMD) using mass spectrometry (MS).

104 igment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry.

105 ages from eyes with nonexudative age-related macular degeneration (AMD) were graded for the presence

106 standard care for patients with age-related macular degeneration (AMD) who are being considered for

107 y SD OCT study participants with age-related macular degeneration (AMD) with bilateral large drusen o

108 iants at 34 loci contributing to age-related macular degeneration (AMD)(1-3).

109 iking phenotypic similarities to age-related macular degeneration (AMD), a common and genetically com

110 t common genetic contributors to age-related macular degeneration (AMD), a leading cause of irreversi

111 Age-related macular degeneration (AMD), a leading cause of irreversi

112 re implicated in the etiology of age-related macular degeneration (AMD), a major cause of blindness i

113 tor contributing to the risk for age-related macular degeneration (AMD), a retinal disease involving

114 as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), are among the leading causes

115 idal neovascularization (CNV) in age-related macular degeneration (AMD), but central questions regard

116 th literacy of 225 patients with age-related macular degeneration (AMD), diabetic macular edema (DME)

117 ng ocular comorbidity other than age-related macular degeneration (AMD), diabetic retinopathy, glauco

118 PPS and to drusen, nonexudative age-related macular degeneration (AMD), exudative AMD, hereditary ma

119 rse range of diseases, including age-related macular degeneration (AMD), glaucoma and refractive erro

120 ic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindnes

121 vent irreversible vision loss in age-related macular degeneration (AMD), it is critical to detect ret

122 genetic variants associated with age-related macular degeneration (AMD), one of the leading causes of

123 t in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory

124 genous retinal detachment (RRD), age-related macular degeneration (AMD), proliferative diabetic retin

125 In age-related macular degeneration (AMD), rare variants in the complem

126 In assessing the severity of age-related macular degeneration (AMD), the Age-Related Eye Disease

127 E) underlies the pathogenesis of age-related macular degeneration (AMD), the leading cause of irrever

128 n implicated in the pathology of age-related macular degeneration (AMD), the most common cause of adu

129 ic loci that are associated with age-related macular degeneration (AMD), the most common cause of inc

130 ntributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusio

131 SFD closely resembles age-related macular degeneration (AMD), which is the leading cause o

132 uited patients with intermediate age-related macular degeneration (AMD), without other vitreoretinal

133 80 years of age or later, showed age-related macular degeneration (AMD)-like fundus changes.

134 link Periodontal disease(PD) to age-related macular degeneration (AMD).

135 x diseases of the eye, including age-related macular degeneration (AMD).

136 al and breast cancers as well as age-related macular degeneration (AMD).

137 key role in the pathogenesis of age-related macular degeneration (AMD).

138 of the human wet, or neovascular age-related macular degeneration (AMD).

139 s, diabetic retinopathy (DR) and age-related macular degeneration (AMD).

140 essive degeneration in aging and age-related macular degeneration (AMD).

141 d to have glaucoma and exudative age-related macular degeneration (AMD).

142 ION in patients with neovascular age-related macular degeneration (AMD).

143 or delay development to advanced age-related macular degeneration (AMD).

144 gement measurements in eyes with age-related macular degeneration (AMD).

145 om eyes with drusen secondary to age-related macular degeneration (AMD).

146 roteins (HDLs) are implicated in age-related macular degeneration (AMD).

147 the induction and progression of age-related macular degeneration (AMD).

148 is pigmentosa (RP), and atrophic age-related macular degeneration (AMD).

149 in their post-nascent stage and age-related macular degeneration (AMD).

150 ajor cause of vision loss in wet age-related macular degeneration (AMD).

151 s from images from patients with Age-related Macular Degeneration (AMD).

152 n OCT findings in the setting of age-related macular degeneration (AMD).

153 tered in patients with exudative age-related macular degeneration (AMD).

154 matory retinal disorders such as age-related macular degeneration (AMD).

155 flammation increases the risk of age-related macular degeneration (AMD).

156 ations in eyes with intermediate age-related macular degeneration (AMD).

157 intakes with a high incidence of age-related macular degeneration (AMD).

158 d lesions which are hallmarks of age-related macular degeneration (AMD).

159 o contribute the pathogenesis of age-related macular degeneration (AMD).

160 ts and graded centrally for late age-related macular degeneration (AMD).

161 e first cell classes affected by age-related macular degeneration (AMD).

162 atrophy (GA) onset secondary to age-related macular degeneration (AMD).

163 ger age than in individuals with age-related macular degeneration (AMD).

164 coherence tomography (SS-OCT) in age-related macular degeneration (AMD).

165 early feature of nonneovascular age-related macular degeneration (AMD).

166 pposed to be a rare condition in age-related macular degeneration (AMD).

167 (Alzheimer's disease) and sight (age-related macular degeneration [AMD]).

168 g the normal and diseased state (age related macular degeneration, AMD) in the retina.

169 years or older with neovascular age-related macular degeneration and a baseline best-corrected visua

170 n C, a recessive risk factor for age-related macular degeneration and Alzheimer's disease, in both in

171 during treatment for neovascular age-related macular degeneration and are associated with poor visual

172 l name, CFH) are associated with age-related macular degeneration and atypical hemolytic uremic syndr

173 Neovascular age-related macular degeneration and diabetic retinopathy are preval

174 al degenerative diseases such as age-related macular degeneration and diabetic retinopathy.

175 s common in eye diseases such as age-related macular degeneration and diabetic retinopathy.

176 t underpin major retinal diseases, including macular degeneration and glaucoma.

177 es for retinal diseases, such as age-related macular degeneration and inherited retinal dystrophies,

178 h age-related phenotypes such as age-related macular degeneration and longevity.

179 ss in many eye diseases, such as age-related macular degeneration and macular telangiectasia.

180 atform for understanding the pathogenesis of macular degeneration and other related degenerative diso

181 nant I62-CFH (protective against age-related macular degeneration) and V62-CFH functioned equivalentl

182 dema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had other causes of

183 oid-associated diseases, including dementia, macular degeneration, and diabetes mellitus, in epidemio

184 ic features, including glaucoma, age-related macular degeneration, and epiretinal membrane, require s

185 Glaucoma, macular degeneration, and near-sightedness searches more

186 including diabetic retinopathy, age-related macular degeneration, and past cataract surgery, were re

187 body donor eyes with neovascular age-related macular degeneration are limited by the time span from d

188 inal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and therefore could

189 d with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degenerati

190 n various pathologies, including age-related macular degeneration, arthritis, and cancer.

191 Eyes with age-related macular degeneration-associated choroidal neovasculariza

192 als to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome

193 Age-related macular degeneration automated detection was applied to

194 ive loss of vision in young males, a form of macular degeneration called X-linked retinoschisis (XLRS

195 f ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic retinopathy, g

196 al diseases such as retinitis pigmentosa and macular degeneration cause irreversible vision loss in m

197 uch as diabetic retinopathies, glaucoma, and macular degeneration, cause the death of retinal neurons

198 ic atrophy is a blinding form of age-related macular degeneration characterized by retinal pigmented

199 n mouse and human eyes, both normal and with macular degeneration/choroidal neovascularization.

200 rd of diabetic macular edema and age-related macular degeneration clinical trials registered on Clini

201 tformin were less likely to have age-related macular degeneration compared with those not taking the

202 tion for Atrophy Associated with Age-Related Macular Degeneration-defined atrophy.

203 iabetic retinopathy, neovascular age-related macular degeneration, diabetic macular edema, and retina

204 dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy and glaucoma)

205 bute to vascular inflammation in age-related macular degeneration, diabetic retinopathy, and glaucoma

206 sting for age, gender, glaucoma, age-related macular degeneration, diabetic retinopathy, cataract, gl

207 ping blinding conditions such as age-related macular degeneration, diabetic retinopathy.

208 Progression to exudative 'wet' age-related macular degeneration (exAMD) is a major cause of visual

209 Age-related macular degeneration features from SD OCT, IR, and color

210 Compared to exudative age-related macular degeneration fewer injections are needed to cont

211 ould be of clinical and research interest in macular degeneration, for example in estimating visual p

212 tinal dystrophies and late-stage age-related macular degeneration, for which treatments remain limite

213 Neovascular age-related macular degeneration-free survival.

214 6 eyes with drusen secondary to age-related macular degeneration from 6 subjects were analyzed.

215 ) published by the International Age-related Macular Degeneration Genomics consortium of 33,526 (16,1

216 d for information on the topics of cataract, macular degeneration, glaucoma, diabetic retinopathy, an

217 without concomitant ocular pathology such as macular degeneration, glaucoma, Sicca syndrome, epiretin

218 telangiectasia type 2 (MacTel), a late-onset macular degeneration, has been linked to a loss in the r

219 roidal neovascularization due to age-related macular degeneration in the study eye were randomized an

220 tinoschisis (XLRS) is one of the most common macular degenerations in young males, with a worldwide p

221 Age-related macular degeneration is a leading cause of vision loss w

222 Age-related macular degeneration is a major cause of vision impairme

223 tages of geographic atrophy (GA) age-related macular degeneration is characterised by the demise of p

224 raphic atrophy (GA) secondary to age-related macular degeneration is considered a single entity.

225 (GA), a progressive dry form of age-related macular degeneration is elusive and there is currently n

226 Neovascular age-related macular degeneration is one of the leading causes of bli

227 Age related macular degeneration is the leading cause of blindness i

228 The other, age-related macular degeneration, is the most common form of blindne

229 ly contributes to vision loss in age-related macular degeneration, is unclear.

230 uro-ophthalmology.(1-5) Humans with juvenile macular degeneration (JMD) show significant blood-oxygen

231 Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multice

232 erited retinal degenerations and age-related macular degeneration.Literature discussed here focuses o

233 Age-related macular degeneration may be more than a "macular" condit

234 presence of coarse stereopsis in humans with macular degeneration (MD), which affects the central ret

235 as a result of uncorrected myopia and myopic macular degeneration (MMD) in 2015.

236 mes in patients with neovascular age-related macular degeneration (nAMD) during anti-vascular endothe

237 ens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (T

238 he natural course of neovascular age-related macular degeneration (nAMD) is essential in discussing p

239 change in real-world neovascular age-related macular degeneration (nAMD) patients.

240 ata of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal af

241 ion in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal in

242 hy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab.

243 d from a registry of neovascular age-related macular degeneration (nAMD) treatment outcomes.

244 mes in patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular e

245 in the management of neovascular age-related macular degeneration (nAMD), diabetic retinal disease (D

246 njection therapy for neovascular age-related macular degeneration (nAMD).

247 ing the treatment of neovascular age-related macular degeneration (nAMD).

248 VEGF) inhibitors for neovascular age-related macular degeneration (nAMD).

249 itivity in eyes with neovascular age-related macular degeneration (nAMD).

250 CA) in patients with neovascular age-related macular degeneration (nAMD).

251 ersus aflibercept in neovascular age-related macular degeneration (nAMD).

252 apy in patients with neovascular age-related macular degeneration (nAMD).

253 igible patients with neovascular age-related macular degeneration (nAMD).

254 for the treatment of neovascular age-related macular degeneration (nAMD).

255 for the treatment of neovascular age-related macular degeneration (nAMD).

256 among patients with neovascular age-related macular degeneration (nAMD).

257 pt monotherapies for neovascular age-related macular degeneration (NVAMD).

258 tion for Atrophy Associated with Age-Related Macular Degeneration on OCT, it is unclear whether decre

259 pigment epithelium in eyes with age-related macular degeneration or central serous chorioretinopathy

260 f age or older with a diagnosis of exudative macular degeneration or diabetic macular edema requiring

261 nts for treatment of neovascular age-related macular degeneration or diabetic macular edema.

262 eases such as Stargardt disease, age-related macular degeneration or retinitis pigmentosa urgently re

263 antly with sets found by GWAS of age-related macular degeneration (P=1.4 x 10(-12)), ulcerative colit

264 several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuri

265 reatment patterns in neovascular age-related macular degeneration patients in 2012-2015.

266 emplary search for patients with age-related macular degeneration, performed cataract surgery, and at

267 rcept injections for neovascular age-related macular degeneration presented 4 weeks after his most re

268 ,188 Medicare beneficiaries with neovascular macular degeneration receiving >=1 anti-vascular endothe

269 Retinal dystrophies and age-related macular degeneration related to photoreceptor degenerati

270 near-sightedness, diabetic retinopathy, and macular degeneration, respectively, with all pairwise co

271 ss of photoreceptors in atrophic age-related macular degeneration results in severe visual impairment

272 from the early drusen stage to the advanced macular degeneration stage that leads to blindness, rema

273 We evaluated 37 eyes with age-related macular degeneration that had serous PED.

274 ssible lack of success in clinical trials in macular degeneration that have targeted inflammatory age

275 In age-related macular degeneration, the retinal pigment epithelium can

276 r age, gender, and a documented diagnosis of macular degeneration, the use of a BLF IOL was not predi

277 urity, diabetic retinopathy, and age-related macular degeneration, threaten the visual health of chil

278 rusen, retinal pigmentary abnormalities, and macular degeneration to age and sex were studied in 4926

279 f treatment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

280 articipants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

281 t study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

282 68 eyes from the Comparison of Age-Related Macular Degeneration Treatments Trials.

283 chedule, and CATT (Comparison of Age-Related Macular Degeneration Treatments) study and VIEW (VEGF Tr

284 ncluding an epiretinal membrane, age-related macular degeneration, vitreomacular traction, and cystoi

285 r inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot o

286 national registry of neovascular age-related macular degeneration was analyzed with an intention-to-t

287 Age-related macular degeneration was assessed using the Wisconsin Ag

288 Age-related macular degeneration was diagnosed and graded based on f

289 lume scans of 1094 patients with age-related macular degeneration, we generated a vocabulary of 20 lo

290 ic multivitamin formulations for age-related macular degeneration were obtained.

291 hy of prematurity (ROP), and wet age-related macular degeneration (wet AMD) have been found to have e

292 r glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for retinitis p

293 Similarities to OCT features in age-related macular degeneration, where mitochondrial dysfunction ha

294 Patients with neovascular age-related macular degeneration who demonstrated a suboptimal respo

295 ophy outcome(s) in patients with age-related macular degeneration who received anti-VEGF treatment we

296 g 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical t

297 ,000 cases of glaucoma, and 117,000 cases of macular degeneration will be present.

298 ether individuals with retinal damage due to macular degeneration will have stereopsis.

299 PCV) is a variant of neovascular age-related macular degeneration with distinct phenotypes, treatment

300 ents may proceed to an early-onset end-stage macular degeneration with frank atrophy of the RPE or ne